TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.
Roman R SchimmerLarisa V KovtonyukNancy KlemmJonas FullinSebastian M StolzJan MuellerFrancisco CaiadoKari J KurppaBenjamin L EbertMarkus G ManzSteffen BoettcherPublished in: Blood advances (2022)